Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysis

Articolo
Data di Pubblicazione:
2026
Citazione:
First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysis / Roessler, N., Maiorano, B.A., Miszczyk, M., Miyajima, K., Inoue, S., Von Deimling, M., Vetterlein, M.W., Fisch, M., Moschini, M., Rajwa, P., Necchi, A., Roupret, M., Pradere, B., D'Andrea, D., Gontero, P., Karakiewicz, P.I., Shariat, S.F.. - In: WORLD JOURNAL OF UROLOGY. - ISSN 0724-4983. - 44:1(2026). [10.1007/s00345-025-06180-5]
Abstract:
Purpose: To evaluate novel intravesical and systemic combination therapies for improving outcomes in BCG-naïve patients with non-muscle invasive bladder cancer (NMIBC), this systematic review and meta-analysis assessed first-line treatment strategies, including combinations with systemic immune-checkpoint inhibitors (ICIs). Methods: In this prospectively registered review (CRD420251163026), MEDLINE, Embase, Web of Science, and the ESMO 2025 abstract book were searched for randomized controlled trials (RCTs) evaluating first-line therapies in BCG-naïve NMIBC. Meta-analyses estimated HRs for recurrence-related time-to-event outcomes (disease-free and event-free survival). Grade ≥ 3 treatment-related adverse events were pooled as relative risks (RRs). Risk of bias was assessed using the Cochrane RoB 2 tool. Results: Out of 5202 records screened, six RCTs including 3485 patients were eligible. Modifications to intravesical BCG alone (three trials, n = 895) did not significantly improve recurrence-related outcomes. Systemic ICIs given additional to intravesical BCG significantly reduced recurrence-related events compared to BCG alone (HR 0.77, 95%CI 0.6–0.97, n = 1899; number needed to treat at two years: 25), but increased grade ≥ 3 treatment-related adverse events by a statistically and clinically significant margin (RR 3.97, 95% CI 2.53–6.22, n = 1879; number needed to treat to harm one patient: 5). Sensitivity analysis using the ALBAN alternative endpoint of high-grade recurrence-free survival yielded HR 0.78 (95% CI 0.59–1.02), not reaching statistical significance. Limitations included heterogeneity in trial design and endpoint definitions. Conclusion: In BCG-naïve NMIBC, systemic ICIs combined with intravesical BCG improve recurrence-related outcomes but are offset by a substantially increased risk of severe treatment-related adverse events. These findings highlight the need for careful, risk-based, biomarker-guided patient selection to balance over- and undertreatment within a shared decision-making process.
Tipologia CRIS:
1.1.1 Articolo in rivista - Review
Elenco autori:
Roessler, N.; Maiorano, B. A.; Miszczyk, M.; Miyajima, K.; Inoue, S.; Von Deimling, M.; Vetterlein, M. W.; Fisch, M.; Moschini, M.; Rajwa, P.; Necchi, A.; Roupret, M.; Pradere, B.; D'Andrea, D.; Gontero, P.; Karakiewicz, P. I.; Shariat, S. F.
Autori di Ateneo:
NECCHI ANDREA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/207918
Link al Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/207918/376263/unpaywall-bitstream-438639501.pdf
Pubblicato in:
WORLD JOURNAL OF UROLOGY
Journal
  • Dati Generali

Dati Generali

URL

https://link.springer.com/article/10.1007/s00345-025-06180-5
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.11.1.0